![](https://cdn.sanity.io/images/0vv8moc6/cancernetwork/71fd5173639e811752b086b41aac15f77b72a258-1200x1200.jpg?fit=crop&auto=format)
Retreatment With Pertuzumab/T-DM1 Improves PFS in HER2+ Breast Cancer
Retreatment with pertuzumab (Perjeta) combined with trastuzumab emtansine (T-DM1) plus physician’s choice of chemotherapy may improve survival outcomes in patients with HER2–positive locally advanced or metastatic breast cancer, according to results from a …